Nanobiotix SA - ADR (OQ:NBTX)
Business Focus: Biotechnology & Medical Research
Apr 24, 2024 04:40 pm ET
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, provided an update on operational progress and...
Apr 17, 2024 04:15 pm ET
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that it will report its...
Apr 10, 2024 04:15 pm ET
Voting Rights and Shares Capital of the Company
Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of Shares OutstandingTotal number of voting rightsTotal voting...
Apr 02, 2024 04:15 pm ET
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced completion of the dose...
Mar 06, 2024 04:15 pm ET
Nanobiotix to Present at Upcoming Investor Conferences in March
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will...
Feb 13, 2024 04:15 pm ET
Voting Rights and Shares Capital of the Company
Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights,...
Jan 31, 2024 04:15 pm ET
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Laurent Levy, co-founder...
Jan 29, 2024 04:15 pm ET
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced achievement of operational...
Jan 11, 2024 04:32 pm ET
Voting Rights and Shares Capital of the Company
Market: Euronext Paris / Nasdaq Euronext Compartment: BISIN code: FR0011341205Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PAWebsite: www.nanobiotix.com...
Dec 26, 2023 02:00 am ET
Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that partner LianBio has...
Dec 13, 2023 04:15 pm ET
Voting Rights and Shares Capital of the Company
Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of Shares Outstanding1Total number of voting rightsTotal voting rights,...
Dec 04, 2023 04:22 pm ET
Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces today the closing of...
Nov 13, 2023 04:15 pm ET
NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational...
Nov 09, 2023 04:15 pm ET
NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that it will report its...
Nov 08, 2023 04:15 pm ET
Voting Rights and Shares Capital of the Company
Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of Shares Outstanding1Total number of voting rightsTotal voting rights,...
Nov 07, 2023 04:01 pm ET
NANOBIOTIX Announces Closing of Global Offering
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the closing today (the...
Nov 02, 2023 10:49 am ET
NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the pricing of its...
Nov 01, 2023 06:30 pm ET
NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the launch, subject to...
Oct 23, 2023 02:00 am ET
NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced updated data from two...
Oct 11, 2023 04:27 pm ET
Voting Rights and Shares Capital of the Company
Market: Euronext Paris / NasdaqEuronext Compartment: BISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights,...
Oct 04, 2023 04:30 pm ET
Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival o
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the final readout on primary...
Sep 29, 2023 04:15 pm ET
NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation O
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the oral presentation of the...
Sep 28, 2023 04:15 pm ET
NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced new clinical data from a...
Sep 26, 2023 04:15 pm ET
NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational...
Sep 19, 2023 04:15 pm ET
Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will report its...
Sep 13, 2023 04:15 pm ET
Voting Rights and Shares Capital of the Company
Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights,...
Sep 05, 2023 04:15 pm ET
NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the appointment of Louis...
Aug 31, 2023 04:15 pm ET
NANOBIOTIX to Present at the H.C. Wainwright 25th Annual Global Investment Conference
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Laurent Levy, co-founder...
Aug 15, 2023 04:15 pm ET
NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today the expiration of the waiting...
Aug 04, 2023 04:15 pm ET
NANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the Company will host an...
Jul 20, 2023 04:15 pm ET
Voting Rights and Shares Capital of the Company
Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights,...
Jul 19, 2023 04:15 pm ET
NANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers
NANOBIOTIX (Euronext: NANO — NASDAQ: NBTX – the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the first patient has been...
Jul 10, 2023 02:00 am ET
NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced a global licensing,...
Jun 08, 2023 04:15 pm ET
Voting Rights and Shares Capital of the Company
Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights,...
May 17, 2023 04:15 pm ET
NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational...
May 05, 2023 01:30 am ET
NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), today announced that the Company is entering into final contract negotiations after agreement to a non-binding term sheet for development and commercialization of lead nanotherapeutic...
Apr 24, 2023 07:33 pm ET
NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results
NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, provided an update on operational progress and...
Apr 17, 2023 04:15 pm ET
NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announces it will issue its financial...
Apr 11, 2023 04:15 pm ET
Voting Rights and Shares Capital of the Company
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) Paris, France, April 11, 2023Market: Euronext Paris /...
Mar 27, 2023 04:15 pm ET
Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the company will...
Mar 14, 2023 04:15 pm ET
Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announces that it will provide an...
Feb 14, 2023 04:15 pm ET
Voting Rights and Shares Capital of the Company
Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of SharesOutstandingTotal number of voting rightsTotal voting...
Jan 11, 2023 04:15 pm ET
Voting Rights and Shares Capital of the Company
Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights,...
Dec 27, 2022 01:45 am ET
NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the first patient in the...
Dec 21, 2022 04:15 pm ET
NANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract Statement
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it has ended the...
Dec 08, 2022 04:15 pm ET
Voting Rights and Shares Capital of the Company
Paris, France, December 8, 2022Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of Shares OutstandingTotal number of voting...
Nov 15, 2022 04:15 pm ET
NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy, co-founder...
Nov 14, 2022 04:15 pm ET
NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced completion of the dose...
Nov 10, 2022 02:00 am ET
NANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of C
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced updated data from the...
Nov 09, 2022 04:15 pm ET
NANOBIOTIX Provides Third Quarter 2022 Operational and Financial Update
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational...
Nov 08, 2022 04:15 pm ET
NANOBIOTIX Voting Rights and Shares Capital of the Company
Market: Euronext Paris / NasdaqEuronext Compartment: BISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of SharesOutstandingTotal number of voting rightsTotal voting...
Nov 02, 2022 04:15 pm ET
NANOBIOTIX Appoints Renowned Global Experts to Comprehensive Scientific Advisory Board for Potential First-in-Class Radioenhancer NBTXR3
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the appointment of twelve (12)...
Oct 31, 2022 04:15 pm ET
NANOBIOTIX to Present at the Jefferies London Healthcare Conference
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy,...
Oct 27, 2022 04:15 pm ET
NANOBIOTIX to Announce Third Quarter 2022 Financial Results on November 9, 2022
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will report its...
Oct 18, 2022 04:15 pm ET
NANOBIOTIX Executes Definitive Agreement to Restructure Existing Loan With the European Investment Bank
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced execution of a final...
Oct 10, 2022 04:15 pm ET
Nanobiotix: Voting Rights and Shares Capital of the Company
Regulatory News:
Sep 28, 2022 04:15 pm ET
Sep 22, 2022 04:15 pm ET
Sep 21, 2022 04:15 pm ET
Sep 12, 2022 02:00 am ET
Sep 08, 2022 04:15 pm ET
Nanobiotix: Voting Rights and Shares Capital of the Company
Regulatory News:
Sep 07, 2022 04:15 pm ET
Sep 06, 2022 04:15 pm ET
Aug 31, 2022 04:15 pm ET
Aug 09, 2022 04:15 pm ET
NANOBIOTIX: Voting Rights and Shares Capital of the Company
Regulatory News:
Jul 13, 2022 04:15 pm ET
Jun 09, 2022 04:15 pm ET
Jun 05, 2022 09:00 am ET
Jun 02, 2022 04:15 pm ET
May 18, 2022 09:12 pm ET
May 18, 2022 04:40 pm ET
NANOBIOTIX Provides First Quarter Operational and Financial Update
Regulatory News:
May 17, 2022 04:15 pm ET
May 11, 2022 04:15 pm ET
NANOBIOTIX to Participate in Two Upcoming Investor Conferences
Regulatory News:
May 10, 2022 04:15 pm ET
May 04, 2022 04:15 pm ET
May 02, 2022 04:15 pm ET
Apr 11, 2022 04:15 pm ET
Apr 08, 2022 05:57 pm ET
Apr 07, 2022 04:15 pm ET
Mar 30, 2022 04:21 pm ET
Mar 16, 2022 04:15 pm ET
NANOBIOTIX to Announce Full Year 2021 Financial Results on March 30, 2022
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announces that it will report its financial results for full-year ending December 31, 2021, on Wednesday, Mar
Mar 08, 2022 04:15 pm ET
Feb 10, 2022 04:15 pm ET
Feb 09, 2022 04:15 pm ET
Jan 26, 2022 04:15 pm ET
Jan 11, 2022 04:15 pm ET
Jan 10, 2022 02:00 am ET
Jan 05, 2022 04:15 pm ET
Jan 04, 2022 04:15 pm ET
Dec 08, 2021 04:15 pm ET
Nov 17, 2021 04:15 pm ET
Nov 09, 2021 04:15 pm ET
Nov 08, 2021 04:15 pm ET
Nov 03, 2021 04:15 pm ET
NANOBIOTIX to Participate in a Fireside Chat at the Jefferies London Healthcare Conference
The fireside chat will be webcast live from the Events section of the company’s website at www.nanobiotix.com. A replay of the webcast will be archived and available for one month following the event.
Oct 24, 2021 05:02 pm ET
Oct 20, 2021 04:15 pm ET
NANOBIOTIX Provides Third Quarter Operational and Financial Update
Regulatory News:
Oct 08, 2021 04:15 pm ET
Oct 06, 2021 04:15 pm ET
Sep 28, 2021 04:15 pm ET
Sep 09, 2021 04:15 pm ET
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital as of August 31, 2021
Market: Euronext Paris
Compartment: B
ISIN code: FR0011341205
Website: www.nanobiotix.com
Sep 08, 2021 04:15 pm ET
Sep 07, 2021 04:15 pm ET
Jul 20, 2021 04:15 pm ET
Nanobiotix Provides Second Quarter Operational and Financial Update
Regulatory News:
Jun 30, 2021 04:15 pm ET
Jun 07, 2021 04:15 pm ET
Jun 03, 2021 04:50 pm ET
Jun 01, 2021 04:15 pm ET
May 26, 2021 04:15 pm ET
May 25, 2021 04:15 pm ET
May 21, 2021 06:34 pm ET
May 19, 2021 05:18 pm ET
May 12, 2021 04:15 pm ET
May 11, 2021 05:31 pm ET
May 11, 2021 04:15 pm ET
Apr 29, 2021 04:49 pm ET
NANOBIOTIX Announces First Quarter Operational and Financial Updates
Regulatory News:
Apr 28, 2021 04:15 pm ET
Apr 12, 2021 12:00 pm ET
Nanobiotix Combined Shareholders Meeting to Be Held April 28, 2021
Regulatory News:
Apr 07, 2021 06:27 pm ET
Mar 17, 2021 05:15 pm ET
Mar 04, 2021 05:59 pm ET
NANOBIOTIX and PharmaEngine Mutually Agree to Conclude Collaboration
Regulatory News:
Mar 03, 2021 04:15 pm ET
Mar 02, 2021 04:15 pm ET
Feb 26, 2021 04:15 pm ET
NANOBIOTIX 2020 Q4 and Annual Revenues
Regulatory News:
Jan 28, 2021 04:00 pm ET
Jan 25, 2021 04:00 pm ET
Nanobiotix Subsidiary Curadigm Secures New Collaboration Agreement With Sanofi Focused on Gene Therapy Pipeline
NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a clinical-stage biotechnology company focused on developing first-in-class product candidates that use proprietary nanotechnology to transform cancer treatment, today announced a new collaboration agreement secured by its wholly-owned subsidiary, Curadigm.
Jan 15, 2021 08:00 am ET
Nanobiotix Announces Positive First Results for Novel NBTXR3 in Rectal Cancer Study at ASCO-GI 2021
NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company”), a clinical-stage biotechnology company focused on developing first-in-class product candidates that use proprietary nanotechnology to transform cancer treatment, today announced positive first results from the complete phase Ib part of a phase Ib/II study evaluati
Jan 08, 2021 08:00 am ET
Nanobiotix Announces Key Development Milestones for 2021 After Successful Nasdaq Initial Public Offering
NANOBIOTIX (Paris:NANO) (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a clinical-stage biotechnology company focused on developing first-in-class product candidates that use proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy and increasing the proportion of patients that respond to immune checkpoi
Dec 11, 2020 02:22 am ET
Dec 09, 2020 07:40 pm ET
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.